5 Most Hated Biotechs
Defining “Hatred”
• Biotechs listed on the NASDAQ with largest short
as a percentage of float
• As of latest data availabl...
Myraid Genetics (Nasdaq: MYGN)
• 51.2% of float sold short
• Increase of 0.7% in outstanding short from Jan 15 to
Jan 31
•...
Not a Bad Start to the Year
Sarepta Therapeutics (Nasdaq: SRPT)
• 35.2% of float sold short
• Increase of 5.2% in outstanding shares short from
Jan 15...
Shorts Are Loosing Here Too
Questcor Pharmaceuticals (Nasdaq: QCOR)
• 34.1% of float sold short
• Decrease of 8% in outstanding shares short from
Jan ...
Sometimes One Drug Is All You Need
Ziopharm Oncology (Nasdaq: ZIOP)
• 31.2% of float sold short
• Decrease of 1.4% in outstanding shares short from
Jan 15 to...
Can’t Make Up Our Minds, Can We?
MannKind (Nasdaq: MNKD)
• 30.2% of float sold short
• Decrease of 11.5% in outstanding shares short from
Jan 15 to Jan 31
...
Talk About a Volatile Stock
Buy? Sell? Short?
• A large short interest is a sign that other investors
think shares will go down.
• It’s not a sign tha...
The Motley Fool's chief investment officer
doesn’t think you should short this company.
In fact, it’s his No. 1 stock pick...
Upcoming SlideShare
Loading in...5
×

Short_interestjan31_Orelli_2_18_2014

10,019

Published on

Myraid Genetics, Sarepta Therapeutics, Questcor Pharmaceuticals, Ziopharm Oncology, and MannKind top the list of the most shorted biotechs.

Published in: Economy & Finance
0 Comments
4 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
10,019
On Slideshare
0
From Embeds
0
Number of Embeds
14
Actions
Shares
0
Downloads
16
Comments
0
Likes
4
Embeds 0
No embeds

No notes for slide

Short_interestjan31_Orelli_2_18_2014

  1. 1. 5 Most Hated Biotechs
  2. 2. Defining “Hatred” • Biotechs listed on the NASDAQ with largest short as a percentage of float • As of latest data available on Jan 31, 2014 • Days to cover is defined as the short interest divided by the average daily volume – Longer days to cover can create short squeeze during a rally – Put another way, a longer “days to cover” indicates an increased conviction by short sellers
  3. 3. Myraid Genetics (Nasdaq: MYGN) • 51.2% of float sold short • Increase of 0.7% in outstanding short from Jan 15 to Jan 31 • 24 days to cover short interest • Bear thesis: Competition with Myraid’s BRCA1/BRCA2 test, BRACAnalysis, from other diagnostic test makers. Shares up 50% year to date.
  4. 4. Not a Bad Start to the Year
  5. 5. Sarepta Therapeutics (Nasdaq: SRPT) • 35.2% of float sold short • Increase of 5.2% in outstanding shares short from Jan 15 to Jan 31 • 4 days to cover short interest • Bear thesis: FDA won’t give Sarepta’s Duchenne muscular dystrophy drug eteplirsen an accelerated approval. Shares up 28% year to date.
  6. 6. Shorts Are Loosing Here Too
  7. 7. Questcor Pharmaceuticals (Nasdaq: QCOR) • 34.1% of float sold short • Decrease of 8% in outstanding shares short from Jan 15 to Jan 31 • 8 days to cover short interest • Bear thesis: Government is investigating Questcor’s promotional practices for its only drug Acthar. Shares up 27% year to date.
  8. 8. Sometimes One Drug Is All You Need
  9. 9. Ziopharm Oncology (Nasdaq: ZIOP) • 31.2% of float sold short • Decrease of 1.4% in outstanding shares short from Jan 15 to Jan 31 • 20 days to cover short interest • Bear thesis: Proof of concept clinical trial data on Ad-RTS-IL-12 in breast cancer, melanoma, and/or glioblastoma will fail.
  10. 10. Can’t Make Up Our Minds, Can We?
  11. 11. MannKind (Nasdaq: MNKD) • 30.2% of float sold short • Decrease of 11.5% in outstanding shares short from Jan 15 to Jan 31 • 9 days to cover short interest • Bear thesis: FDA won’t approve MannKind’s inhaled insulin Afrezza and/or the drug will be a commercial flop.
  12. 12. Talk About a Volatile Stock
  13. 13. Buy? Sell? Short? • A large short interest is a sign that other investors think shares will go down. • It’s not a sign that you should sell, but it’s important to investigate the bear thesis further. • In fact, investing against the crowd can be rewarding. A high short interest will exaggerate the move as shorts cover their positions.
  14. 14. The Motley Fool's chief investment officer doesn’t think you should short this company. In fact, it’s his No. 1 stock pick for 2014. You can find out which stock it is in our special free report. Just click the button below.
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×